Literature DB >> 28807572

Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide.

Aya Futamura1, Dai Nozawa2, Yuko Araki2, Yunoshin Tamura2, Seiken Tokura2, Hiroshi Kawamoto2, Yuichi Tokumaru3, Sora Kakihara3, Takeshi Aoki3, Norikazu Ohtake2.   

Abstract

The design, synthesis, and structure activity relationships of the novel class of pyrazolylethylbenzamide orexin receptor 1-selective antagonists are described. Further derivatization of the prototype dual orexin receptor 1/2 antagonist lead (1) by installing a (S)-methyl group into the ethyl linker moiety between the pyrazole ring and benzamide resulted in an increase of the antagonist potency against orexin receptor 1/2 receptors. Optimization of the benzamide and pyrazole parts of compounds 2 and 9b led to the identification of N-ethyl-5-fluoro-N-{(2S)-1-[5-(4-fluorophenyl)-2H-tetrazol-2-yl]propan-2-yl}-2-(pyrimidin-2-yl)benzamide (24), which exhibited excellent antagonistic activity against orexin receptor 1 with an IC50 of 2.01nM and a 265-fold selectivity for orexin receptor 1 over orexin receptor 2.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dual orexin receptor antagonist (DORA); Orexin 1; Selective orexin receptor antagonist (SORA)

Mesh:

Substances:

Year:  2017        PMID: 28807572     DOI: 10.1016/j.bmc.2017.07.051

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

Review 1.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

Review 2.  Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.

Authors:  Yu Sun; Ryan K Tisdale; Thomas S Kilduff
Journal:  Front Neurol Neurosci       Date:  2021-05-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.